To appraise the clinical and cost effectiveness of atezolizumab in combination within its marketing authorisation for treating advanced non-squamous non-small-cell lung cancer
 
Status In progress
Process STA pre-2018
ID number 1210

Provisional Schedule

Expected publication 05 June 2019

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews

Consultees

Companies sponsors Roche (atezolizumab)
Others Department of Health and Social care
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Psychosocial Oncology Society
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Associated public health groups None
Comparator companies Merck Sharp & Dohme (pembrolizumab)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
02 May 2019 - 15 May 2019 Final appraisal document
20 March 2019 Committee meeting
11 February 2019 - 04 March 2019 Appraisal consultation
17 January 2019 Committee meeting: 1
24 October 2018 The company who produces atezolizumab, Roche, have provided an update on regulatory timings. As a consequence, this appraisal has been rescheduled to better align with these and the first committee meeting has been scheduled for 17 January 2019.
11 July 2018 Invitation to participate
10 April 2018 - 09 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
01 March 2017 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance